Novo Nordisk ends Hims & Hers tie-up over copycat Wegovy drugs
Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments
Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments
Shares in US company fall 16% after FDA announces investigation into unregulated medication
US telehealth group and Danish drugmaker have been in dispute over copycat medicines
Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy
US telehealth group will sell product for $49 a month, a third that of its Danish competitor
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy
